Search Results for "Chemotherapy Resistant Lymphoma T Cell"
Matching Channels
Lymphoma is a cancer of the lymph nodes; classified as Hodgkin or non-Hodgkin lymphoma. Malignancy varies, and the prognosis can be from a few months to many years. Symptoms include enlarged lymph...
Hodgkin Lymphoma is a disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be l...
Matching News
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activ...
Weill Cornell research team develops new experimental drug therapy to target DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activ...
Novel drug therapy targets aggressive form of non-Hodgkin's lymphoma
(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh...
New way to kill lymphoma without chemotherapy
(Northwestern University) Scientists annihilated lymphoma by depriving it of a favorite food: HDL cholesterol. Northwestern researchers developed a new golden nanoparticle that's a replica of natural...
New way to kill lymphoma without chemotherapy: Golden nanoparticle starves cancer cell to death
Scientists annihilated lymphoma by depriving it of a favorite food: HDL cholesterol. Researchers developed a new golden nanoparticle that's a replica of natural HDL. Acting like a secret double agent,...
Potential key to new treatment for mantle cell lymphoma (MCL)
Researchers have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-...
NCI long-term study a positive result for BiovaxID
Phase II BiovaxID® lymphoma vaccine clinical trial results, presented by the NCI, demonstrated that vaccination following rituximab combination chemotherapy induced nearly universal T-cell immune res...
Lymphoma Drug GCS-100 Seems Promising After Discovery Of New Mechanism
Researchers at Jonsson Comprehensive Cancer Center at UCLA have discovered the mechanism by which an experimental drug, GCS-100, removes a protein from lymphoma cells that prevents the cells from resp...
Matching PubMed Articles
Mantle cell lymphoma (MCL) is a rare but aggressive form of B cell non-Hodgkin lymphoma in which therapy resistance is common. New therapeutic options have extended survival in refractory MCL but have...
Abstract PURPOSE: 1) To assess treatment response and overall outcome in a cohort of patients with relapsed and refractory peripheral T cell lymphoma. 2) To compare the results with diffuse large B ce...
Subcutaneous panniculitis-like T cell lymphoma (SPTL) is a rare subtype of non-Hodgkin lymphoma for which a definitive therapeutic strategy has not been established yet. We report a case of chemothera...
We describe a case of reactivation of hepatitis D virus (HDV) in a patient treated with chemotherapy for a diffuse large B cell lymphoma despite lamivudine prophylaxis. This case suggests that previou...
